This article from Charles River Laboratories dives into how NGS is transforming adventitious virus testing, offering greater sensitivity and comprehensive detection compared to traditional methods. As NGS continues to play a pivotal role in biosafety, this insight aligns with our dedication to providing advanced solutions for biologics safety and quality.

Sep 17, 2024 |Charles River Laboratories

Next-Gen Sequencing for Adventitious Virus Testing

This highly effective testing method removes animal testing from product release requirements, a 3Rs plus

For decades, vaccine developers relied on animals to test whether their products contained adventitious viruses—the scientific term for viruses that unintentionally get introduced into the manufacturing process. Laboratories historically used a combination of in vivo, in vitro and PCR—a tool that amplifies a segment of DNA—to track these unwanted microorganisms.

But a new tool is stepping up and taking its place in a big way. Innovative next-generation sequencing (NGS) approaches have been developed that can detect live viral contaminants in cells, and regulatory bodies are encouraging its use as a replacement for in vivo assays. Two of Charles River’s Biologics experts, Olaf Stamm, PhD, Technical Business Development Director and Horst Ruppach, PhD, Scientific and Portfolio Executive Director with Global Biologics, answer some of the frequently asked questions that clients…